CORALVILLE — When it comes to admitting how much they smoke or drink, people aren’t always the most truthful.
IDx, a privately-held AI diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo request to market IDx-DR, an AI-based diagnostic system for the autonomous detection of diabetic retinopathy, a leading cause of blindness. IDx-DR is the first autonomous, AI-based diagnostic system authorized for commercialization by the FDA.
IDx, a University of Iowa spinout company based in Coralville, has received FDA approval to market IDX-DR, the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.
Coralville-based SynderBio was awarded the top company award at this year's Partnering For Growth Biotech Innovation Showcase held in Ankeny on Tuesday.
THIS MARKS THE FIFTH YEAR THAT MEDIREVV HAS BEEN RANKED IN THE TOP THREE!
Coralville, IA – February 28, 2018– MediRevv, a healthcare revenue cycle management company, has been ranked second in the “Extended Business Office” category of the 2017/2018 Best in KLAS: Software and Services Report, February 2018.
MediRevv debuted on the KLAS list in 2013/2014 ranking third. In the 2014/2015 Best in KLAS report, they moved into the second position for the first time. Of note, MediRevv has held the second place ranking for four years running.
CORALVILLE, Iowa, Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz™ for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).
- Combination creates the premier provider of high-tech IT solutions to Government Technology Services market
- With approximately $9.9 billion in revenue and strong double-digit EBITDA margins, the combined GDIT and CSRA is well-positioned to serve its customers’ current and evolving mission requirements
- Expected to generate run-rate pre-tax cost synergies of approximately 2% of combined sales by 2020
- Accretive to earnings and free cash flow per share in 2019